Atea Pharmaceuticals, Inc.

NasdaqGS:AVIR Stock Report

Market Cap: US$234.5m

Atea Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:AVIR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
10 Apr 25BuyUS$0Bradley RadoffIndividual265,000US$2.92
02 Apr 25BuyUS$29,005Radoff Family Foundation, Endowment ArmCompany10,000US$2.90
12 Mar 25BuyUS$0Bradley RadoffIndividual275,100US$3.03
10 Mar 25BuyUS$159,440Nerium Capital LLCCompany54,000US$2.98
07 Mar 25BuyUS$30,215Radoff Family Foundation, Endowment ArmCompany10,000US$3.02
03 Mar 25BuyUS$945,510JEC II Associates LLCCompany300,000US$3.15
26 Feb 25BuyUS$5,314,277Bradley RadoffIndividual1,495,000US$3.55
25 Feb 25BuyUS$438,777Radoff Family Foundation, Endowment ArmCompany135,000US$3.25
16 Jan 25BuyUS$81,499Franklin BergerIndividual25,000US$3.36
10 Dec 24SellUS$1,023,475Franklin BergerIndividual359,606US$2.85
20 Jun 24SellUS$61,144Bruce PolskyIndividual17,544US$3.49
05 Jun 24SellUS$4,024Jean-Pierre SommadossiIndividual1,006US$4.00

Insider Trading Volume

Insider Buying: AVIR insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of AVIR?
Owner TypeNumber of SharesOwnership Percentage
Hedge Funds7,609,8128.89%
Individual Insiders11,560,46113.5%
General Public19,191,13722.4%
Institutions47,218,06555.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 68.65% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.5%
BlackRock, Inc.
8,943,065US$24.5m-1.31%no data
8.89%
BML Capital Management, LLC
7,609,812US$20.9m0.02%16.93%
7.21%
Jean-Pierre Sommadossi
6,166,965US$16.9m0%no data
7.03%
FMR LLC
6,017,993US$16.5m-6.34%no data
5.61%
Tang Capital Management, LLC
4,800,000US$13.2m0.23%0.67%
5.52%
The Vanguard Group, Inc.
4,727,702US$13.0m1.3%no data
3.7%
Bradley Radoff
3,165,100US$8.7m9.14%no data
2.9%
Bain Capital Life Sciences Investors, LLC
2,485,638US$6.8m0%0.99%
2.31%
Geode Capital Management, LLC
1,977,337US$5.4m3.16%no data
2.07%
State Street Global Advisors, Inc.
1,770,688US$4.9m-0.86%no data
1.52%
JEC II Associates LLC
1,300,000US$3.6m0%50.22%
1.49%
Renaissance Technologies LLC
1,278,400US$3.5m5.08%no data
1.38%
Dimensional Fund Advisors LP
1,183,726US$3.2m21.1%no data
1.09%
Acadian Asset Management LLC
932,925US$2.6m0%0.01%
0.84%
Andrea Corcoran
717,307US$2.0m0%no data
0.84%
Almitas Capital LLC
715,005US$2.0m-4.92%0.38%
0.81%
Northern Trust Global Investments
690,175US$1.9m-2.09%no data
0.71%
Charles Schwab Investment Management, Inc.
607,882US$1.7m-7.83%no data
0.68%
Federated Hermes, Inc.
582,729US$1.6m-0.04%no data
0.68%
Newtyn Management, LLC
580,000US$1.6m0%0.18%
0.63%
JP Morgan Asset Management
535,537US$1.5m0%no data
0.62%
Two Sigma Advisers, LP
533,000US$1.5m7.98%no data
0.58%
CM Management, LLC
500,000US$1.4m66.7%1.41%
0.56%
Franklin Berger
476,897US$1.3m0%no data
0.53%
Peapod Lane Capital LLC
452,060US$1.2m37.6%1.45%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 10:03
End of Day Share Price 2025/05/19 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atea Pharmaceuticals, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric JosephJ.P. Morgan
Matthew HarrisonMorgan Stanley
Maxwell SkorMorgan Stanley